Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-pVAX1 Vaccine Against Crimean Congo Hemorrhagic Fever
NCT06684431Phase 1Completed
- Sponsor
- Karolinska Institutet
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of N-pVAX1 in Crimean–Congo hemorrhagic fever (CCHF), sponsored by Karolinska Institutet. Primary endpoints: Local reactions, Visual analogue scale and 3 more. Started Nov 2024; status: completed.
02
Drugs
N-pVAX1
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)
Beyond the preview
Go deeper on NCT06684431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684431.